Ruchi Bhatia1, Sravanthi Ravulapati2, Alex Befeler1, John Dombrowski3, Sameer Gadani4, Nishant Poddar5. 1. Division of Gastrointestinal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO, 63110, USA. 2. Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapies, Saint Louis University School of Medicine, 3655 Vista Avenue, 3rd Floor, St. Louis, MO, 63110, USA. 3. Department of Radiation Oncology, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO, 63110, USA. 4. Department of Radiology, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO, 63110, USA. 5. Division of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapies, Saint Louis University School of Medicine, 3655 Vista Avenue, 3rd Floor, St. Louis, MO, 63110, USA. nishant.poddar@health.slu.edu.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) represents one of the most common causes of cancer-related deaths worldwide, with rising incidence in the USA. Bone metastases with HCC, in particular, have an extremely poor prognosis. We present prevalence, treatment, and survival of patients with bone and more specifically spinal metastases from HCC. METHODS: A retrospective analysis was done at a single tertiary care institution of patients with bone metastases from HCC between January 2005 and December 2015. RESULTS: Among 1017 patients with HCC, 20 were found to have bone metastases of which 11 had spinal metastases. Seventeen (85%) were male, with median age of 58 years at time of HCC diagnosis. Systemic chemotherapy and sorafenib were used in 12 (60%) patients, and 12 (60%) received radiation therapy. Among patients who did not receive therapy, median survival was 76 days. Median survival after diagnosis of metastasis in patients on sorafenib and radiation were 106 and 100 days, respectively. CONCLUSION: Bone metastases in HCC are very rare and aggressive. Due to its rarity, optimal treatment strategies are not well defined. Early diagnosis is important for optimal therapy and improved survival.
BACKGROUND:Hepatocellular carcinoma (HCC) represents one of the most common causes of cancer-related deaths worldwide, with rising incidence in the USA. Bone metastases with HCC, in particular, have an extremely poor prognosis. We present prevalence, treatment, and survival of patients with bone and more specifically spinal metastases from HCC. METHODS: A retrospective analysis was done at a single tertiary care institution of patients with bone metastases from HCC between January 2005 and December 2015. RESULTS: Among 1017 patients with HCC, 20 were found to have bone metastases of which 11 had spinal metastases. Seventeen (85%) were male, with median age of 58 years at time of HCC diagnosis. Systemic chemotherapy and sorafenib were used in 12 (60%) patients, and 12 (60%) received radiation therapy. Among patients who did not receive therapy, median survival was 76 days. Median survival after diagnosis of metastasis in patients on sorafenib and radiation were 106 and 100 days, respectively. CONCLUSION:Bone metastases in HCC are very rare and aggressive. Due to its rarity, optimal treatment strategies are not well defined. Early diagnosis is important for optimal therapy and improved survival.
Authors: Hollins P Clark; W Forrest Carson; Peter V Kavanagh; Coty P H Ho; Perry Shen; Ronald J Zagoria Journal: Radiographics Date: 2005-10 Impact factor: 5.333
Authors: V Satya Suresh Attili; K Govind Babu; D Lokanatha; P P Bapsy; C Ramachandra; H Rajshekar Journal: J Cancer Res Ther Date: 2008 Apr-Jun Impact factor: 1.805
Authors: Robert S Brown; K Shiva Kumar; Mark W Russo; Milan Kinkhabwala; Dianne L Rudow; Patricia Harren; Steven Lobritto; Jean C Emond Journal: Liver Transpl Date: 2002-03 Impact factor: 5.799
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Ruben Van den Brande; Erwin Mj Cornips; Marc Peeters; Piet Ost; Charlotte Billiet; Erik Van de Kelft Journal: J Bone Oncol Date: 2022-07-09 Impact factor: 4.491